AAPL   324.55 (-0.18%)
MSFT   184.85 (-0.28%)
FB   230.16 (+0.00%)
GOOGL   1,431.67 (-0.53%)
AMZN   2,490.86 (+0.50%)
NVDA   349.86 (-0.26%)
BABA   217.10 (-0.69%)
MU   48.83 (-0.18%)
GE   7.33 (-0.41%)
TSLA   893.10 (+1.15%)
AMD   53.21 (+0.91%)
T   31.37 (-0.48%)
ACB   14.10 (-1.40%)
F   6.21 (+0.32%)
GILD   74.32 (-0.11%)
DIS   122.56 (+0.31%)
NFLX   426.40 (+1.05%)
BAC   25.78 (-0.81%)
BA   184.64 (+6.63%)
AAPL   324.55 (-0.18%)
MSFT   184.85 (-0.28%)
FB   230.16 (+0.00%)
GOOGL   1,431.67 (-0.53%)
AMZN   2,490.86 (+0.50%)
NVDA   349.86 (-0.26%)
BABA   217.10 (-0.69%)
MU   48.83 (-0.18%)
GE   7.33 (-0.41%)
TSLA   893.10 (+1.15%)
AMD   53.21 (+0.91%)
T   31.37 (-0.48%)
ACB   14.10 (-1.40%)
F   6.21 (+0.32%)
GILD   74.32 (-0.11%)
DIS   122.56 (+0.31%)
NFLX   426.40 (+1.05%)
BAC   25.78 (-0.81%)
BA   184.64 (+6.63%)
AAPL   324.55 (-0.18%)
MSFT   184.85 (-0.28%)
FB   230.16 (+0.00%)
GOOGL   1,431.67 (-0.53%)
AMZN   2,490.86 (+0.50%)
NVDA   349.86 (-0.26%)
BABA   217.10 (-0.69%)
MU   48.83 (-0.18%)
GE   7.33 (-0.41%)
TSLA   893.10 (+1.15%)
AMD   53.21 (+0.91%)
T   31.37 (-0.48%)
ACB   14.10 (-1.40%)
F   6.21 (+0.32%)
GILD   74.32 (-0.11%)
DIS   122.56 (+0.31%)
NFLX   426.40 (+1.05%)
BAC   25.78 (-0.81%)
BA   184.64 (+6.63%)
AAPL   324.55 (-0.18%)
MSFT   184.85 (-0.28%)
FB   230.16 (+0.00%)
GOOGL   1,431.67 (-0.53%)
AMZN   2,490.86 (+0.50%)
NVDA   349.86 (-0.26%)
BABA   217.10 (-0.69%)
MU   48.83 (-0.18%)
GE   7.33 (-0.41%)
TSLA   893.10 (+1.15%)
AMD   53.21 (+0.91%)
T   31.37 (-0.48%)
ACB   14.10 (-1.40%)
F   6.21 (+0.32%)
GILD   74.32 (-0.11%)
DIS   122.56 (+0.31%)
NFLX   426.40 (+1.05%)
BAC   25.78 (-0.81%)
BA   184.64 (+6.63%)
Log in

NASDAQ:ANIPANI Pharmaceuticals Stock Price, Forecast & News

$30.46
+0.38 (+1.26 %)
(As of 06/4/2020 09:49 AM ET)
Add
Compare
Today's Range
$29.80
Now: $30.46
$30.48
50-Day Range
$30.23
MA: $36.64
$50.10
52-Week Range
$28.28
Now: $30.46
$86.96
Volume11,206 shs
Average Volume148,127 shs
Market Capitalization$368.87 million
P/E RatioN/A
Dividend YieldN/A
Beta1.45
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. The company was founded in 2001 and is headquartered in Baudette, Minnesota.
Read More
ANI Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.64 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ANIP
Previous SymbolNASDAQ:BPAX
CUSIPN/A
Phone218-634-3500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$206.55 million
Cash Flow$8.14 per share
Book Value$17.59 per share

Profitability

Net Income$6.09 million

Miscellaneous

Employees299
Market Cap$368.87 million
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive ANIP News and Ratings via Email

Sign-up to receive the latest news and ratings for ANIP and its competitors with MarketBeat's FREE daily newsletter.

ANI Pharmaceuticals (NASDAQ:ANIP) Frequently Asked Questions

How has ANI Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

ANI Pharmaceuticals' stock was trading at $38.30 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ANIP shares have decreased by 20.5% and is now trading at $30.46. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of ANI Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ANI Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for ANI Pharmaceuticals.

When is ANI Pharmaceuticals' next earnings date?

ANI Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for ANI Pharmaceuticals.

How were ANI Pharmaceuticals' earnings last quarter?

ANI Pharmaceuticals Inc (NASDAQ:ANIP) posted its earnings results on Thursday, May, 7th. The specialty pharmaceutical company reported $1.04 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.89 by $0.15. The specialty pharmaceutical company had revenue of $49.77 million for the quarter, compared to analysts' expectations of $49.40 million. ANI Pharmaceuticals had a positive return on equity of 23.92% and a negative net margin of 0.67%. View ANI Pharmaceuticals' earnings history.

What price target have analysts set for ANIP?

3 brokerages have issued 12 month price objectives for ANI Pharmaceuticals' stock. Their forecasts range from $40.00 to $58.00. On average, they anticipate ANI Pharmaceuticals' stock price to reach $49.00 in the next twelve months. This suggests a possible upside of 60.9% from the stock's current price. View analysts' price targets for ANI Pharmaceuticals.

Has ANI Pharmaceuticals been receiving favorable news coverage?

News articles about ANIP stock have trended somewhat negative on Thursday, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ANI Pharmaceuticals earned a media sentiment score of -1.9 on InfoTrie's scale. They also assigned headlines about the specialty pharmaceutical company a news buzz of 8.0 out of 10, indicating that recent press coverage is very likely to have an impact on the stock's share price in the near future. View the latest news aboutANI Pharmaceuticals.

Who are some of ANI Pharmaceuticals' key competitors?

What other stocks do shareholders of ANI Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ANI Pharmaceuticals investors own include Abraxas Petroleum (AXAS), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Teva Pharmaceutical Industries (TEVA), Broadcom (AVGO), AbbVie (ABBV), Cisco Systems (CSCO), Intel (INTC) and NXP Semiconductors (NXPI).

Who are ANI Pharmaceuticals' key executives?

ANI Pharmaceuticals' management team includes the following people:
  • Mr. Arthur S. Przybyl, Pres, CEO & Director (Age 62)
  • Mr. Stephen P. Carey, CFO & VP of Fin. (Age 48)
  • Mr. James G. Marken, Sr. VP of Operations & Product Devel. (Age 56)
  • Mr. Robert W. Schrepfer, Sr. VP of Bus. Devel. & Specialty Sales (Age 47)

What is ANI Pharmaceuticals' stock symbol?

ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."

Who are ANI Pharmaceuticals' major shareholders?

ANI Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (12.03%), State Street Corp (2.69%), First Manhattan Co. (2.23%), Invesco Ltd. (2.20%), Global Alpha Capital Management Ltd. (1.80%) and Geode Capital Management LLC (1.13%). Company insiders that own ANI Pharmaceuticals stock include Arthur Przybyl, David Nash, James G Marken, Meridian Venture Partners Ii L, Robert W Schrepfer and Thomas Haughey. View institutional ownership trends for ANI Pharmaceuticals.

Which major investors are selling ANI Pharmaceuticals stock?

ANIP stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., BlackRock Inc., Wells Fargo & Company MN, THB Asset Management, Morgan Stanley, New York State Common Retirement Fund, Parametric Portfolio Associates LLC, and State Board of Administration of Florida Retirement System. View insider buying and selling activity for ANI Pharmaceuticals.

Which major investors are buying ANI Pharmaceuticals stock?

ANIP stock was acquired by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Federated Hermes Inc., Foundry Partners LLC, AQR Capital Management LLC, Global Alpha Capital Management Ltd., Pictet Asset Management Ltd., SG Americas Securities LLC, and Acadian Asset Management LLC. Company insiders that have bought ANI Pharmaceuticals stock in the last two years include David Nash, and Thomas Haughey. View insider buying and selling activity for ANI Pharmaceuticals.

How do I buy shares of ANI Pharmaceuticals?

Shares of ANIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is ANI Pharmaceuticals' stock price today?

One share of ANIP stock can currently be purchased for approximately $30.46.

How big of a company is ANI Pharmaceuticals?

ANI Pharmaceuticals has a market capitalization of $368.87 million and generates $206.55 million in revenue each year. The specialty pharmaceutical company earns $6.09 million in net income (profit) each year or $4.46 on an earnings per share basis. ANI Pharmaceuticals employs 299 workers across the globe.

What is ANI Pharmaceuticals' official website?

The official website for ANI Pharmaceuticals is www.anipharmaceuticals.com.

How can I contact ANI Pharmaceuticals?

ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The specialty pharmaceutical company can be reached via phone at 218-634-3500 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.